Furthermore, a recent clinical study in women with obesity treated with semaglutide showed improved recognition of basic tastes, altered gene expression in the tongue (measured by tongue biopsy), decreased activation of putamen in response to calorie-dense sweet and savory food cues, and increased cortical brain activity in response to the sweet taste stimulus compared to placebo
GPR75 Antagonists: Genetic studies have linked loss-of-function mutations in the GPR75 gene to lower body weight, making it an attractive target for drug development
It took years of research to develop a formulation that temporarily changes the stomach environment, protects the drug from being broken down and allows enough semaglutide to be absorbed to have a therapeutic effect. The Pill Era Begins In late-stage trials, patients taking the highest oral dose of Wegovy lost about 14 percent of their body weight, results comparable to the injectable version
However, since the rapid, ongoing growth in prescribing these medications, little research has been done on whether it is safe to continue the medication prior to an anesthetic or should it be withheld for a defined period of time